部門紹介

印刷

臨床部

最終更新日 : 2025年6月18日

部の紹介

がん化学療法センターは、「今後のがん治療の最終目標は化学療法である。制がん剤を速やかに開発すべく、日米科学協力計画のもと、基礎部門と臨床部門との有機的連携による研究開発体制の構築とこの事業の発展を進める必要がある。」との当時のがん研究所所長であった吉田富三先生の強い信念がもとになり設立されました。がん化学療法センター設立当初から臨床部が設置されており、それは、新しく開発された抗癌剤の造血器腫瘍、その他固形腫瘍を用いた臨床研究とともに、得られた知見から基礎研究へ重要な問題の還元が期待されていたためである。歴代の部長のもとで、新規薬剤の開発や細胞死、細胞療法などの臨床研究の基礎となる研究を継続しており、病院部門と協力しながら基礎研究と臨床の橋渡しにつながる研究を広く行っています。

研究内容目次

＊臨床部の一部の研究員は病院との兼務のため他のラボと役職表記が異なります。臨床をしながら研究を行っています。

代表論文

研究業績へ

2025年｜2024年｜2023年｜2022年｜2021年｜2020年｜2019年｜2018年｜2017年｜2016年｜2015年｜2014年｜2013年｜2012年｜2011年｜2010年｜2009年

2025年

Yanai, Y., Kosaka, T., Mikami, S., Arai, M., Watanabe, K., Takeda, T., Matsumoto, K., Yamashita, M., Kitano, S., Oya, M.
Dynamics in the Prostate Immune Microenvironment Induced by Androgen Deprivation Therapy.
Prostate, 85 (3): 308-314, 2025
Yuko Mishima, Yuko Shirouchi, Tomoko Takayama, Sayuri Minowa, Yuko Ishihara, Kei Hirano, Mitsuhito Hirano, Kikuaki Yoshida, Yukako Teramoto, Nobuhiko Yamauchi, Siew-Kee Low, Dai Maruyama.
Impact of NRAS mutation on efficacy of triplet induction therapy in newly diagnosed multiple myeloma . J Clin Exp Hematop. 2025;65(1):72-76. doi: 10.3960/jslrt.24077.

2024年

Kato, S., Shigematsu, Y., Saito, R., Ito, H., Inamura, K.
Schistosoma japonicum-related hepatitis: potential contributor to hepatocellular carcinoma.
QJM, 117 (10): 737-738, 2024
Shigematsu, Y., Saito, R., Amori, G., Kanda, H., Takahashi, Y., Takeuchi, K., Takahashi, S., Inamura, K.
Fusobacterium nucleatum, immune responses, and metastatic organ diversity in colorectal cancer liver metastasis.
Cancer Sci, 115 (10): 3248-3255, 2024
Shigematsu, Y., Saito, R., Kanda, H., Takahashi, Y., Takeuchi, K., Takahashi, S., Inamura, K.
Inverse Correlation between pks-Carrying Escherichia coli Abundance in Colorectal Cancer Liver Metastases and the Number of Organs Involved in Recurrence.
Cancers (Basel), 16 (17): 3003, 2024
Shiraishi, A., Oh-Hara, T., Takahashi, Y., Uchibori, K., Nishio, M., Katayama, R.
3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer.
Biochem Biophys Res Commun, 725 (17): 150255, 2024
Takahashi, Y., Morimura, R., Tsukamoto, K., Gomi, S., Kato, A., Mizukami, M., Naito, Y., Irie, S., Nagayama, S., Shinozaki, E., Yamaguchi, K., Fujita, N., Kitano, S., Katayama, R., Matsusaki, M.
In vitro throughput screening of anticancer drugs using patient-derived cell lines cultured on vascularized three-dimensional stromal tissues.
Acta Biomater, 183: 111-129, 2024
Ikarashi, D., *Kitano, S., Tsuyukubo, T., Yamashita, M., Matsuura, T., Maekawa, S., Kato, R., Kato,
Y., Kanehira, M., Takata, R., Sugai, T., Obara, W.
Pathological complete response to neoadjuvant chemotherapy may improve antitumor immune response
via reduction of regulatory T cells in muscle-invasive bladder cancer. Sci. Rep., 14 (1): 1442, 2024

2023年

Chan, H. T., Nagayama, S., *Otaki, M., Chin, Y. M., Fukunaga, Y., Ueno, M., Nakamura, Y., Low, S. K.
Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients. Front. Oncol., 12: 1055968, 2023

2022年

Kojima, T., Kato, K., Hara, H., *Takahashi, S., Muro, K., Nishina, T., Wakabayashi, M., Nomura, S., Sato, A., Ohtsu, A., *Doi, T.
Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303). Esophagus, 19: 702-710. 2022
Shirouchi, Y., *Mishima, Y., Takayama, T., Minowa, S., Ishihara, Y., Tamba, M., Hirano, M., Onda, N., Takeuchi, K., Maruyama, D.
Serum cell-free DNA concentration as a possible prognostic marker in newly diagnosed diffuse large B-cell lymphoma. Biomed. Res., 43: 99-106. 2022
Takemoto, A., Takagi, S., Ukaji, T., Gyobu, N., Kakino, M., Takami, M., Kobayashi, A., Lebel, M., Kawaguchi, T., Sugawara, M., Tsuji-Takayama, K., Ichihara, K., Funauchi, Y., Ae, K., Matsumoto, S., Sugiura, Y., Takeuchi, K., Noda, T., Katayama, R., *Fujita, N.
Podoplanin antibody for osteosarcoma treatment. Clin. Cancer Res., 28: 2633-2645. 2022

2021年

Takagi, S., Sasaki, Y., Koike, S., Takemoto, A., Seto, Y., Haraguchi, M., Ukaji, T., Kawaguchi, T., Sugawara, M., Saito, M., Funauchi, Y., Ae, K., Matsumoto, S., *Fujita, N., Katayama, R.
Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis. Oncogene 40: 5548-5558. 2021
Ukaji, T., Takemoto, A., Shibata, H., Kakino, M., Takagi, S., Katayama, R., *Fujita, N.
Novel knock-in mouse model for the evaluation of therapeutic efficacy and toxicity of human podoplanin-targeting agents. Cancer Sci. 112: 2299-2313 (2021)
*Mishima, Y., Mishima, Y., Shirouchi, Y., Nishimura, N., Yokoyama, M., Okabe, T., Inoue, N., Uryu, H., Fukuta, T., Hatake, K., Terui, Y.
The clonal evolution during long-term clinical course of multiple myeloma. Int. J. Hematol. 113: 279-284 (2021)

2020年

Nosol, K., Romane, K., Irobalieva, R.N., Alam, A., Kowal, J., Fujita, N., *Locher, K.P.
Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1. Proc. Natl. Acad. Sci. USA 117: 26245-26253 (2020)

2019年

Yokoyama M, Kusano Y, Nishihara A, Inoue N, Nishimura N, Mishima Y, Terui Y, Nukada T, Nomura T, Hatake K.
Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
Support Care Cancer. 2019 May 15. doi: 10.1007/s00520-019-04802-4. (2019)

このページのTOPへ

2018年

Kusano Y, Yokoyama M, Inoue N, Yamauchi H, Takahashi A, Tsuyama N, Mishima Y, Nishimura N, Takeuchi K, Terui Y, Hatake K.
Delayed recovery of serum immunoglobulin G is a poor prognostic marker in patients with follicular lymphoma treated with rituximab maintenance.
Ann Hematol. 2018 Feb;97(2):289-297. (2018 )

このページのTOPへ

2017年

K. Hosoya, S. Matsusaka, T. Kashiwada, K. Suzuki, N. Ureshino, A. Sato, Y. Miki, K. Kitera, M. Hirai, K. Hatake, S. Kimura and N. Sueoka-Aragane.
Detection of KRAS mutations in plasma DNA using a fully automated Rrpid detection system in colorectal cancer patients.
Pathol. Oncol. Res., in press (2017)
Mishima Y, Terui Y, Yokoyama M, Nishimura N, Ueda K, Kusano Y, Yamauchi H, Inoue N, Takahashi A, Tsuyama N, Mishima Y, Takeuchi K, Hatake K.
Bearing 19q13 aberration predicts poor prognosis in non-germinal centre type of CD5+ DLBCL.
Br J Haematol. doi: 10.1111/bjh.15001. [Epub ahead of print] No abstract available. (2017)
Yokoyama M, Kusano Y, Takahashi A, Inoue N, Ueda K, Nishimura N, Mishima Y, Terui Y, Nukada T, Nomura T, Hatake K.
Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
Support Care Cancer. 2017 Nov;25(11):3313-3320. (2017)
Tsuyama N, Sakata S, Baba S, Mishima Y, Nishimura N, Ueda K, Yokoyama M, Terui Y, Hatake K, Kitagawa M, Ishizuka N, Tomita N, Takeuchi K.
BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.
Blood. 130(4):489-500. (2017)
Mishima Y, Matsusaka S, Chin K, Mikuniya M, Minowa S, Takayama T, Shibata H, Kuniyoshi R, Ogura M, Terui Y, Mizunuma N, Hatake K.
Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
Target Oncol. 12(3):341-351. (2017)
Tsuyama N, Ennishi D, Yokoyama M, Baba S, Asaka R, Mishima Y, Terui Y, Hatake K, Takeuchi K.
Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Oncotarget. 8(20):33487-33500. (2017)
Mishima Y, Terui Y, Yokoyama M, Nishimura N, Ueda K, Kusano Y, Yamauchi H, Inoue N, Takahashi A, Tsuyama N, Mishima Y, Takeuchi K, Hatake K.
Bearing 19q13 aberration predicts poor prognosis in non-germinal centre type of CD5+ DLBCL.
Br J Haematol. doi: 10.1111/bjh.15001. (2017)
Yokoyama M, Kusano Y, Takahashi A, Inoue N, Ueda K, Nishimura N, Mishima Y, Terui Y, Nukada T, Nomura T, Hatake K.
Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
Support Care Cancer. 2017 Nov;25(11):3313-3320. (2017)
Tsuyama N, Sakata S, Baba S, Mishima Y, Nishimura N, Ueda K, Yokoyama M, Terui Y, Hatake K, Kitagawa M, Ishizuka N, Tomita N, Takeuchi K.
BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.
Blood. 130(4):489-500. (2017)
Mishima Y, Matsusaka S, Chin K, Mikuniya M, Minowa S, Takayama T, Shibata H, Kuniyoshi R, Ogura M, Terui Y, Mizunuma N, Hatake K.
Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
Target Oncol. 12(3):341-351. (2017)
Sugihara T, Koizumi M, Koyama M, Terauchi T, Gomi N, Ito Y, Hatake K, Sata N.
Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors.
Ann Nucl Med. 31(10):719-725. doi: 10.1007/s12149-017-1202-3. (2017)

このページのTOPへ

2016年

Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type. Dobashi A, Tsuyama N, Asaka R, Togashi Y, Ueda K, Sakata S, Baba S, Sakamoto K, Hatake K, Takeuchi K.
Genes Chromosomes Cancer. 2016 May;55(5):460-71. doi: 10.1002/gcc.22348. Epub 2016 Feb 10.
Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer.
Fukada I, Araki K, Kobayashi K, Shibayama T, Takahashi S, Horii R, Akiyama F, Iwase T, Ohno S, Hatake K, Hozumi Y, Sata N, Ito Y.
PLoS One. 2016 Sep 15;11(9):e0162616. doi: 10.1371/journal.pone.0162616.

このページのTOPへ

2015年

Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. Osumi H, Shinozaki E, Osako M, Kawazoe Y, Oba M, Misaka T, Goto T, Kamo H, Suenaga M, Kumekawa Y, Ogura M, Ozaka M, Matsusaka S, Chin K, Hatake K, Mizunuma N.
Mol Clin Oncol. 2015 Sep;3(5):1053-1057. Epub 2015 Jul 9.
Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Kobayashi K, Ito Y, Matsuura M, Fukada I, Horii R, Takahashi S, Akiyama F, Iwase T, Hozumi Y, Yasuda Y, Hatake K.
Surg Today. 2015 Oct 14.
Suzuki SI, Matsusaka S, Hirai M, Shibata H, Takagi K, Mizunuma N, Hatake K.
A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction. Int J Oncol. 2015 Apr 30. doi: 10.3892/ijo.2015.2978. [Epub ahead of print]

このページのTOPへ

2014年

Matsusaka S, Kozuka M, Takagi H, Ito H, Minowa S, Hirai M, Hatake K.
A novel detection strategy for living circulating tumor cells using 5-aminolevulinic acid. Cancer Lett. 2014 Dec 1;355(1):113-20. doi: 10.1016/j.canlet.2014.09.009.
Kodama T, Motoi N, Ninomiya H, Sakamoto H, Kitada K, Tsukaguchi T, Satoh Y, Nomura K, Nagano H, Ishii N, Terui Y, Hatake K, Ishikawa Y.
A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line. J Thorac Oncol. 2014 Nov;9(11):1638-46. doi: 10.1097/JTO.0000000000000311.

2013年

kuboki Y, Matsusaka S, Minowa S, Shibata H, Suenaga M, Shinozaki E, Mizunuma N, Ueno M, Yamaguchi T, Hatake K.
Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. Anticancer Res. 2013 Sep;33(9):3905-10.
Takagi S, Sato S, Oh-hara T, Takami M, Koike S, Mishima Y, Hatake K, Fujita N.
Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One. 2013 Aug 21;8(8):e73609. doi: 10.1371/journal.pone.0073609.

このページのTOPへ

2012年

Mishima Y, Terui Y, Mishima Y, Kuniyoshi R, Matsusaka S, Mikuniya M, Kojima K, Hatake K.
High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism. Int Immunol. 2012 Mar 21. [Epub ahead of print]
Harada Y, Ishii I, Hatake K, Kasahara T.
Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3. Cancer Lett. 1;319(1):83-8. 2012

2011年

Mishima Y, Terui Y, Takeuchi K, Matsumoto-Mishima Y, Matsusaka S, Utsubo-Kuniyoshi R and Hatake K.
The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations. Blood Cancer Journal (2011) 1, e15
Matsusaka S, Mishima Y, Suenaga M, Terui Y, Kuniyoshi R, Mizunuma N, Hatake K.
Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab. Cancer. 2011 Sep 1;117(17):4026-32.
Yuasa T, Takahashi S, Hatake K, Yonese J, Fukui I.
Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer. Cancer Sci. 2011 102(11):1949-57.
Takaba J, Mishima Y, Hatake K, Kasahara T.
Role of bone marrow-derived monocytes/macrophages in the repair of mucosal damage caused by irradiation and/or anticancer drugs in colitis model. Mediators Inflamm. 2010;2010:634145.

このページのTOPへ

2010年

Matsusaka, S., Chin, K., Ogura, M., Suenaga, M., Shinozaki, E., Mishima, Y., Terui, Y., Mizunuma, N., Hatake, K.
Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer.
Cancer Sci, 101, 1067-1071 (2010)

このページのTOPへ

2009年

Mishima, Y., Sugimura, N., Matsumoto-Mishima, Y., Terui, Y., Takeuchi, K., Asai, S., Ennishi, D., Asai, H., Yokoyama, M., Kojima, K., Hatake, K.
An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Clin Cancer Res, 15, 3624-3632 (2009)
Terui, Y., Mishima, Y., Sugimura, N., Kojima, K., Sakurai, T., Kuniyoshi, R., Taniyama, A., Yokoyama, M., Sakajiri, S., Takeuchi, K., Watanabe, C., Takahashi, S., Ito, Y., Hatake, K.
Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
Clin Cancer Res, 15, 2523-2530 (2009)

このページのTOPへ

企業の方へ

抗がん剤研究や、抗がん剤治療に関する臨床データや臨床サンプルを用いた研究や、ゲノムやプロテオミクスに関して、共同研究に興味のある方は、下記連絡先までご連絡下さい。

共同研究に関して

連絡先

藤田 直也(部長代行)
〒135-8550 東京都江東区有明3-8-31
Tel: 03-3520-0111(代) Fax:03-3570-0465
E-mail：naoya.fujita@jfcr.or.jp

このページのTOPへ